Association between circadian gene CLOCK and cisplatin resistance in ovarian cancer cells: A preliminary study

Xu,Hai; Wang,Zhiyin; Mo,Guoyan; Chen,Hao

doi:10.3892/ol.2018.8488

Association between circadian gene CLOCK and cisplatin resistance in ovarian cancer cells: A preliminary study

Authors:
- Hai Xu
- Zhiyin Wang
- Guoyan Mo
- Hao Chen
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Huangjiahu Hospital, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, P.R. China, China Key Laboratory of TCM Resource and Prescription, Hubei University of Chinese Medicine, Ministry of Education, Wuhan, Hubei 430065, P.R. China, Department of Gastrointestinal Surgery, Jingzhou Central Hospital, Jingzhou, Hubei 434020, P.R. China
Published online on: April 13, 2018 https://doi.org/10.3892/ol.2018.8488
Pages: 8945-8950
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to observe the expression of circadian gene clock circadian regulator (CLOCK) in ovarian cancer cells and the effects of circadian gene CLOCK on cis‑dichlorodiamine platinum (cisplatin) resistance in ovarian cancer cells. The expression of CLOCK mRNA and protein in cisplatin‑sensitive A2780 and cisplatin‑resistant CP70 cells were detected by quantitative polymerase chain reaction and western blot assay. Cisplatin‑sensitive A2780 and cisplatin‑resistant CP70 cells were treated with different concentrations of cisplatin for 48 h, and the expression of hCLOCK protein in the two types of cells was detected by western blot assay. RNA interference method was used to knock down the expression of CLOCK in cisplatin‑resistant CP70 cells. Subsequently, the cisplatin‑resistant CP70 cells were treated with cisplatin. The proliferation of cisplatin‑resistant CP70 cells was observed following treatment with cisplatin. The expression of CLOCK mRNA was significantly higher in cisplatin‑resistant CP70 cells (1.58±0.49) compared with cisplatin‑sensitive A2780 cells (0.44±0.13) (P<0.01). Western blot assay results demonstrated that the expression of CLOCK protein was significantly greater in the cisplatin‑resistant CP70 cells (1.47±0.34) compared with the cisplatin‑sensitive A2780 cells (0.48±0.15) (P<0.01). Following the treatment of A2780 and CP70 cells with cisplatin, CLOCK protein expression increased with an increased concentration of cisplatin, in a dose‑dependent manner (P<0.01). Following the knockdown of CLOCK in cisplatin‑resistant CP70 cells by RNA interference, cisplatin treatment was able to significantly inhibit the proliferation of cells and induce apoptosis (P<0.01). The expression of circadian gene CLOCK in ovarian cancer cells was strongly associated with cisplatin resistance. The upregulation of circadian gene CLOCK in ovarian cancer cells may reduce its sensitivity to cisplatin treatment.

View Figures

View References

1	Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Brawley OW and Wender RC: Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 67:100–121. 2017. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
3	Knutson KL, Karyampudi L, Lamichhane P and Preston C: Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev. 34:53–74. 2015. View Article : Google Scholar : PubMed/NCBI
4	Killedar A, Stutz MD, Sobinoff AP, Tomlinson CG, Bryan TM, Beesley J, Chenevix-Trench G, Reddel RR and Pickett HA: A common cancer risk-associated allele in the hTERT locus encodes a dominant negative inhibitor of telomerase. PLoS Genet. 11:e10052862015. View Article : Google Scholar : PubMed/NCBI
5	Yan C, Yang F, Zhou C, Chen X, Han X, Liu X, Ma H and Zheng W: MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer. Int J Clin Exp Pathol. 8:2710–2718. 2015.PubMed/NCBI
6	Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust KM, Limbart DM, Rödel F, Wezel F, Haferkamp A and Cinatl J Jr: Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics. Transl Oncol. 8:210–216. 2015. View Article : Google Scholar : PubMed/NCBI
7	Takano M, Kakizoe S, Kawami M, Nagai J, Patanasethnont D, Sripanidkulchai B and Yumoto R: Modulation of P-glycoprotein function and multidrug resistance in cancer cells by Thai plant extracts. Pharmazie. 69:823–828. 2014.PubMed/NCBI
8	Territo PR, Maluccio M, Riley AA, McCarthy BP, Fletcher J, Tann M, Saxena R and Skill NJ: Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma. BMC Med Imaging. 15:152015. View Article : Google Scholar : PubMed/NCBI
9	Jing X, Zhang H, Hu J, Su P, Zhang W, Jia M, Cheng H, Li W and Zhou G: β-arrestin 2 is associated with multidrug resistance in breast cancer cells through regulating MDR1 gene expression. Int J Clin Exp Pathol. 8:1354–1363. 2015.PubMed/NCBI
10	Sun Y, Liu JH, Jin L, Sui YX, Han LL and Huang Y: Effect of autophagy-related beclin1 on sensitivity of cisplatin-resistant ovarian cancer cells to chemotherapeutic agents. Asian Pac J Cancer Prev. 16:2785–2791. 2015. View Article : Google Scholar : PubMed/NCBI
11	Sun Y, Liu JH, Jin L, Sui YX, Lai L and Yang Y: Inhibition of Beclin 1 expression enhances cisplatin-induced apoptosis through a mitochondrial-dependent pathway in human ovarian cancer SKOV3/DDP cells. Oncol Res. 21:261–269. 2014. View Article : Google Scholar : PubMed/NCBI
12	Song JM, Hu X, Fu X, Liu K and Li GM: Effects of circadian genes hClock and hBmal1 on migration and invasion of SGC-7901 cells. Xiandai Zhongliu Yixue. 21:2678–2681. 2013.
13	Hu ML, Yeh KT, Lin PM, Hsu CM, Hsiao HH, Liu YC, Lin HY, Lin SF and Yang MY: Deregulated expression of circadian clock genes in gastric cancer. BMC Gastroenterol. 14:672014. View Article : Google Scholar : PubMed/NCBI
14	Filipski E, Subramanian P, Carrière J, Guettier C, Barbason H and Lévi F: Circadian disruption accelerates liver carcinogenesis in mice. Mutat Res. 680:95–105. 2009. View Article : Google Scholar : PubMed/NCBI
15	Fang L, Yang Z, Zhou J, Tung JY, Hsiao CD, Wang L, Deng Y, Wang P, Wang J and Lee MH: Circadian clock gene cry2 degradation is involved in chemoresistance of colorectal cancer. Mol Cancer Ther. 14:1476–1487. 2015. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Yan-Hong H, Jing L, Hong L, Shan-Shan H, Yan L and Ju L: Association between alcohol consumption and the risk of ovarian cancer: A meta-analysis of prospective observational studies. BMC Public Health. 15:2232015. View Article : Google Scholar : PubMed/NCBI
18	Cui X, Li L, Yan G, Meng K, Lin Z, Nan Y, Jin G and Li C: High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma. BMC Cancer. 15:2442015. View Article : Google Scholar : PubMed/NCBI
19	Gao L, Ye X, Ma RQ, Cheng HY, Han HJ, Cui H, Wei LH and Chang XH: Low programmed cell death 5 expression is a prognostic factor in ovarian cancer. Chin Med J (Engl). 128:1084–1090. 2015. View Article : Google Scholar : PubMed/NCBI
20	Lambrechts S, Lambrechts D, Despierre E, Van Nieuwenhuysen E, Smeets D, Debruyne PR, Renard V, Vroman P, Luyten D, Neven P, et al: Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. BMC Pharmacol Toxicol. 16:22015. View Article : Google Scholar : PubMed/NCBI
21	Rooth C: Ovarian cancer: Risk factors, treatment and management. Br J Nurs. 22:S23–S30. 2013. View Article : Google Scholar : PubMed/NCBI
22	Zhang Q, Burdette JE and Wang JP: Integrative network analysis of TCGA data for ovarian cancer. BMC Syst Biol. 8:13382014. View Article : Google Scholar : PubMed/NCBI
23	Longoria TC and Eskander RN: Immune checkpoint inhibition: Therapeutic implications in epithelial ovarian cancer. Recent Pat Anticancer Drug Discov. 10:133–144. 2015. View Article : Google Scholar : PubMed/NCBI
24	Jung H, Choe Y, Kim H, Park N, Son GH, Khang I and Kim K: Involvement of CLOCK: BMAL1 heterodimer in serum-responsive mPer1 induction. Neuroreport. 14:15–19. 2003. View Article : Google Scholar : PubMed/NCBI
25	Bjarnason GA, Jordan RC and Sothern RB: Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am J Pathol. 154:613–622. 1999. View Article : Google Scholar : PubMed/NCBI
26	Uth K and Sleigh R: Deregulation of the circadian clock constitutes a significant factor in tumorigenesis: A clockwork cancer. Part II. In vivo studies. Biotechnol Biotechnol Equip. 28:379–386. 2014. View Article : Google Scholar : PubMed/NCBI
27	Tavano F, Pazienza V, Fontana A, Burbaci FP, Panebianco C, Saracino C, Lombardi L, De Bonis A, di Mola FF, di Sebastiano P, et al: SIRT1 and circadian gene expression in pancreatic ductal adenocarcinoma: Effect of starvation. Chronobiol Int. 32:497–512. 2015. View Article : Google Scholar : PubMed/NCBI
28	Wang F, Li C, Yongluo and Chen L: The circadian gene clock plays an important role in cell apoptosis and the DNA damage response in vitro. Technol Cancer Res Treat. 15:480–486. 2016. View Article : Google Scholar : PubMed/NCBI